Why is Platinum Chemo Effective for BRCA Cancers?

Platinum-based chemotherapies, such as carboplatin and cisplatin, are highly effective against BRCA-mutated cancers because they exploit the tumor’s specific genetic weakness. While these drugs cause severe DNA damage to all cells in the body, BRCA-mutated cancer cells have lost their ability to repair this specific type of damage ^[1]. This vulnerability causes the tumor cells to die off, while your healthy tissues—though still affected by the treatment—are better equipped to recover ^[2].

How Platinum Chemotherapy Damages DNA

Platinum-based chemotherapy drugs work by binding directly to the DNA inside your cells. They create strong chemical bridges—called interstrand crosslinks—that lock the two strands of DNA together ^[3].

When a cell prepares to divide and multiply, it must first “unzip” its DNA to copy it. The crosslinks created by platinum drugs act like a jammed zipper, physically blocking the cell from copying its genetic instructions ^[3][1]. If a cell cannot remove these crosslinks, it cannot divide, and it eventually undergoes a natural self-destruction process.

The BRCA Vulnerability: Homologous Recombination Deficiency (HRD)

In a healthy cell, DNA crosslinks are a highly manageable problem. Healthy cells use a complex repair system called homologous recombination (HR) to cut out the crosslinks and flawlessly repair the DNA ^[3]. The BRCA1 and BRCA2 proteins are essential tools in this repair system ^[1].

Cancers driven by a BRCA mutation, however, have a broken repair system. Because these cancer cells lack functional BRCA proteins, they suffer from homologous recombination deficiency (HRD) ^[4]. When platinum chemotherapy creates crosslinks in their DNA, the cancer cells simply cannot fix the damage ^[1][4]. The genetic damage accumulates rapidly, causing the tumor cells to die.

How Your Healthy Cells Recover (And Why Side Effects Happen)

A common question from patients with an inherited genetic mutation is: “If I have a BRCA mutation, won’t my healthy cells die from this chemotherapy too?”

In hereditary breast and ovarian cancer syndrome, a person typically inherits one mutated copy of a BRCA gene and one perfectly normal copy. Your healthy, non-cancerous cells still have that one normal backup copy. This working copy produces enough healthy BRCA protein to perform homologous recombination and repair the platinum-induced damage ^[2]. For patients whose BRCA mutation is only in the tumor (a somatic mutation), the healthy cells naturally have two normal working copies.

The cancer cells, however, have lost that healthy backup copy—creating a state known as selective vulnerability, where the chemotherapy is uniquely lethal to the cancer cells ^[2].

However, this does not mean your healthy cells escape completely unharmed. Platinum chemotherapy is strong and affects all rapidly dividing cells in the body. While your healthy cells can repair the DNA damage over time, the temporary damage is what causes common chemotherapy side effects, such as fatigue, nausea, lowered blood counts, and nerve tingling (neuropathy) ^[5].

Clinical Benefits and Next Steps

Because of this targeted vulnerability, BRCA-mutated breast and ovarian cancers tend to have significantly higher response rates to platinum-based chemotherapies compared to cancers without these mutations ^[6][7].

Additionally, if a tumor shrinks in response to platinum therapy, it is often a strong indicator that the cancer is highly dependent on this broken repair pathway ^[7]. This helps your oncology team determine if you might also benefit from other targeted treatments, such as PARP inhibitors. PARP inhibitors exploit the exact same genetic weakness and are often prescribed as a daily maintenance therapy after you finish your intravenous chemotherapy ^[7][8]. While BRCA-mutated patients may experience somewhat higher rates of anemia during platinum therapy, chemotherapy dosing does not generally need to be altered compared to non-carriers ^[5].